FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
11.40
+0.33 (2.98%)
At close: Oct 8, 2025, 4:00 PM EDT
11.08
-0.33 (-2.85%)
After-hours: Oct 8, 2025, 6:31 PM EDT
FibroGen Revenue
FibroGen had revenue of $1.35M in the quarter ending June 30, 2025, with 35.07% growth. This brings the company's revenue in the last twelve months to $7.35M, down -200.44% year-over-year. In the year 2024, FibroGen had annual revenue of $29.62M, down -36.71%.
Revenue (ttm)
$7.35M
Revenue Growth
-200.44%
P/S Ratio
6.26
Revenue / Employee
$32,649
Employees
225
Market Cap
46.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
FGEN News
- 14 days ago - FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer - GlobeNewsWire
- 6 weeks ago - FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - GlobeNewsWire
- 2 months ago - FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - FibroGen to Report Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 4 months ago - FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewsWire